Zimbabwe has rejected a significant American healthcare agreement valued at $367m (£272m) over five years because of Washington's request for sensitive data.
This rejection was revealed after a official document dated December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "skewed".
A government representative later stated that the United States was requesting genetic material for scientific study and commercial purposes but refused to guarantee the resulting advantages from future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged further dialogue to reach a agreement acceptable to all parties so the nation's critical HIV programme can be sustained.
Broader Background
This rejection comes after a comparable situation in Kenya, where a court halted a related health funding agreement following concerns were filed about the security of citizens' health data.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and responsibility.
As per statements, Sixteen nations in Africa have so far signed similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
This assistance for Zimbabwe would have gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any equivalent assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," Mangwana explained.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be available to our people if a new disease outbreak emerge."
National Interest and International Frameworks
He also noted that the American exit from the global health body and its pursuit of bilateral deals were disrupting structures previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This framework is designed to guarantee that when a country provides its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as opposition to America," he added.
"We welcome further dialogue with our American counterparts on how subsequent collaboration could be structured in a way that honours the independence and interests of each country."
Health Experts Reaction
Medical experts stated it understood the government's concerns, but recommended that negotiations need to persist considering a large portion of the country's Aids initiatives depended on international support.
"Where technical issues exist, including those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," the group commented.
This impasse underscores the complex challenges between receiving crucial international aid and protecting local interests in an ever more data-driven world.